Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05526755 · ClinicalTrials.gov registry record · Phase 2
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
A Phase 2 study of Stage II-IIIB Non-small Cell Lung Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT05526755: Active Phase 2 study of Stage II-IIIB Non-small Cell Lung Carcinoma, sponsored by AstraZeneca.
NCT05526755 is a Phase 2 study of Stage II-IIIB Non-small Cell Lung Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 188 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05526755, a Phase 2 study of Stage II-IIIB Non-small Cell Lung Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.
Primary Outcome
Defined as time from date of first dose until disease recurrence, or death due to any cause in the absence of recurrence.
Conditions Studied
Interventions
- DRUG Osimertinib 80 mg/40 mg
Study Locations (20)
Other
- Research Site - Hong Kong
- Research Site - Hong Kong
- Research Site - Hong Kong
- Research Site - Avellino
- Research Site - Brescia
- Research Site - Lecce
- Research Site - Milan
- Research Site - Naples
- Research Site - Palermo
- Research Site - Peschiera del Garda
- Research Site - Reggio Emilia
- Research Site - Sondrio
- Research Site - Terni
- Research Site - Udine
- Research Site - Kuala Lumpur
- Research Site - Kuantan
- Research Site - Kuching
California
- Research Site - Santa Rosa
Nevada
- Research Site - Las Vegas
New York
- Research Site - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2029-11-22 |
| Phase | Phase 2 |
What the registry record for NCT05526755 still lists
NCT05526755 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% higher).
The record links to 1 condition, with Stage II-IIIB Non-small Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Osimertinib 80 mg/40 mg is the first listed.
NCT05526755 names 20 study sites across 4 states, led by Other, California, Nevada.
Frequently Asked Questions
What is clinical trial NCT05526755 about?
NCT05526755 is a clinical study titled "A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)". To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.
What is the current status of trial NCT05526755?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2023-03-06. Estimated completion is 2029-11-22.
What conditions does trial NCT05526755 study?
This clinical trial studies the following conditions: Stage II-IIIB Non-small Cell Lung Carcinoma.
What interventions are being tested in trial NCT05526755?
The interventions under investigation include: Osimertinib 80 mg/40 mg (DRUG).
Who is sponsoring clinical trial NCT05526755?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05526755 being conducted?
This trial has 20 study locations across California, Nevada, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05526755's enrollment target sits among peer trials
188 356th of 2000 higher than 1,644 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI